A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma

LESSONS LEARNED. Patients with hepatocellular carcinoma (HCC) often have limited therapeutic responses to the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor sorafenib, which is standard of care in advanced HCC. Targeting the activin receptor‐like kinase 1 (ALK1) and VEGF pathway...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Abou‐Alfa, Ghassan K., Miksad, Rebecca A., Tejani, Mohamedtaki A., Williamson, Stephen, Gutierrez, Martin E., Olowokure, Olugbenga O., Sharma, Manish R., El Dika, Imane, Sherman, Matthew L., Pandya, Shuchi S.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6369956/
https://ncbi.nlm.nih.gov/pubmed/30352941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0654
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados